MariMed Q4 revenue beats estimates
Overview
US cannabis operator's Q4 revenue rose, beating analyst expectations
Q4 adjusted EBITDA missed analyst expectations
2025 wholesale revenue increased 11%
Outlook
MariMed expects growth from adult-use cannabis sales in Delaware throughout 2026
Company sees additional revenue from brand distribution in Maine and new Ohio dispensary
MariMed aims to protect margins and maintain strong liquidity amid sector volatility
Result Drivers
WHOLESALE GROWTH - Co said 2025 wholesale revenue rose 11% and distribution expanded to 85% of dispensaries in core markets
PRICING PRESSURE - Co stated continued pricing pressure across many cannabis markets in the year
Company press release: ID:nGNX5s6T4n
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $41.7 mln | $40.60 mln (3 Analysts) |
Q4 Adjusted Net Income | Beat | $2.2 mln | -$3.18 mln (2 Analysts) |
Q4 Net Income |
| -$4.6 mln |
|
Q4 Adjusted EBITDA | Miss | $4.4 mln | $5.12 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for MariMed Inc is $0.17, about 102.8% above its March 10 closing price of $0.08
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
